Article Text
PDF
Statistics from Altmetric.com
The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some of the key changes that have been made to BNF content since the last print edition (BNF 77) was published.
New monographs
Ertugliflozin (Steglatro)
A new addition to the sodium-glucose co-transporter 2 (SGLT2) inhibitors family, for the treatment of type 2 diabetes mellitus in adults, either as monotherapy (if metformin is deemed inappropriate due to intolerance or contra-indications) or in combination with insulin or other antidiabetic drugs if existing treatment fails to achieve adequate glycaemic control.
Hypoglycaemia is a side effect of ertugliflozin when used in combination with insulin or a sulfonylurea. Therefore, concomitant insulin or drugs that stimulate insulin secretion may require dose reduction.
A drug safety update from the Medicines and Healthcare products Regulatory Agency (MHRA)/Commission on Human Medicines (CHM) reports Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum), a rare but serious and potentially life-threatening infection with SGLT2 inhibitors. For further information please visit: https://www.gov.uk/drug-safety-update
Insulin glargine with lixisenatide (Suliqua)
A novel medicinal combination containing a long-acting recombinant human insulin analogue and a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist …